Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Placebo and nocebo effects in the neurological practice.
NG2-glia and their functions in the central nervous system.
Impact of high intensity exercise on muscle morphology in EAE rats.
[Criteria of ineffectiveness of treatment with first-line therapy: how to use MRI results in decision making?]
Neurobiology: Myelin Goes Where the Action Is.
Oral corticosteroids for multiple sclerosis relapse.
Anti-MOG antibodies with longitudinally extensive transverse myelitis preceded by CLIPPERS.
Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis.
Protein-based classifier to predict conversion from clinically isolated syndrome to multiple sclerosis.
Olig1 Acetylation and Nuclear Export Mediate Oligodendrocyte Development.
GABAergic Agonists Modulate the Glutamate Release from Frontal Cortex Synaptosomes of Rats with Experimental Autoimmune Encephalomyelitis.
Production of IL-27 in multiple sclerosis lesions by astrocytes and myeloid cells: Modulation of local immune responses.
Beneficial effect of a multimerized immunoglobulin Fc in an animal model of inflammatory neuropathy (experimental autoimmune neuritis).
Rituximab for tumefactive demyelination refractory to corticosteroids and plasma exchange.
The rehabilitation of the multiple sclerosis patient.
Smoking and risk of treatment-induced neutralizing antibodies to interferon β-1a.
Urinary complications and risk factors in symptomatic multiple sclerosis patients. Study of a cohort of 328 patients.
Novel advances in the diagnosis and treatment of neuromyelitis optica: is there a need to redefine the gold standard?
Promoting Remyelination in Multiple Sclerosis-Recent Advances.
Changes in functional network centrality underlie cognitive dysfunction and physical disability in multiple sclerosis.
Theiler's murine encephalomyelitis virus as an experimental model system to study the mechanism of blood-brain barrier disruption.
White Matter Changes in Patients with Friedreich Ataxia after Treatment with Erythropoietin.
Disclosure of diagnosis of multiple sclerosis in the workplace positively affects employment status and job tenure.
Exacerbation of Experimental Autoimmune Encephalomyelitis in the Absence of Breast Regression Protein 39/Chitinase 3-Like 1.
Register-based incidence of multiple sclerosis in Brittany (north-western France), 2000-2001.
Pages
« first
‹ previous
…
521
522
523
524
525
526
527
528
529
…
next ›
last »